Table 4. PSM based on Child-Pugh A patients.
| Variable | Child-Pugh A patients | Propensity-score-matched cohort (1:1) | |||||
|---|---|---|---|---|---|---|---|
| ALBI-1 [246] | ALBI-2 [152] | P value | ALBI-1 [113] | ALBI-2 [113] | P value | ||
| Male (%) | 196 (79.7) | 108 (71.1) | 0.065 | 83 (73.5) | 81 (71.7) | 0.881 | |
| Age (years) | 58.11 (8.30) | 59.45 (8.81) | 0.128 | 59.33 (7.83) | 58.48 (9.20) | 0.455 | |
| Tumor number (%) | 0.655 | 0.985 | |||||
| 1 | 196 (79.7) | 119 (78.3) | 87 (77.0) | 88 (77.9) | |||
| 2 | 39 (15.9) | 23 (15.1) | 21 (18.6) | 20 (17.7) | |||
| 3 | 11 (4.5) | 10 (6.6) | 5 (4.4) | 5 (4.4) | |||
| Tumor size (cm) | 2.47 (0.82) | 2.32 (0.76) | 0.061 | 2.40 (0.81) | 2.36 (0.76) | 0.684 | |
| AFP (ng/mL) | 116.51 (321.84) | 116.39 (278.06) | 0.997 | 137.91 (407.75) | 121.28 (300.49) | 0.727 | |
| HBV/HCV infection (%) | 229 (93.1) | 98 (93.4) | 1.000 | 105 (92.9) | 106 (93.8) | 1.000 | |
| PLT (×109/L) | 129.17 (55.36) | 94.31 (61.72) | <0.001 | 97.16 (41.48) | 94.04 (52.71) | 0.621 | |
| ALT (U/L) | 34.24 (37.49) | 35.85 (25.25) | 0.640 | 34.27 (27.97) | 32.95 (21.90) | 0.692 | |
| AST (U/L) | 33.09 (25.71) | 40.66 (25.09) | 0.004 | 35.57 (23.65) | 36.67 (20.39) | 0.707 | |
| ALP (U/L) | 86.44 (30.73) | 104.93 (45.89) | <0.001 | 96.39 (35.69) | 92.06 (30.33) | 0.327 | |
| GGT (U/L) | 58.61 (82.88) | 87.85 (143.63) | 0.010 | 76.22 (103.99) | 64.95 (73.56) | 0.348 | |
| NLR | 2.62 (1.50) | 2.52 (1.71) | 0.574 | 2.70 (1.38) | 2.62 (1.81) | 0.688 | |
| Creatine (μmol/L) | 69.41 (16.71) | 65.33 (26.50) | 0.060 | 67.47 (17.94) | 66.94 (29.74) | 0.871 | |
PSM, propensity-score matching; ALBI, albumin-bilirubin; AFP, alpha-fetoprotein; HBV, hepatitis B virus; HCV, hepatitis C virus; PLT, platelet; AST, aspartic transaminase; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; NLR neutrophil-lymphocyte ratio.